Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:company
|
| gptkbp:CEO |
Dr. Michael Ramroth
|
| gptkbp:country |
gptkb:Germany
|
| gptkbp:focusArea |
immunology
hematology intensive care medicine |
| gptkbp:foundedYear |
1946
|
| gptkbp:headquartersLocation |
Dreieich, Germany
|
| https://www.w3.org/2000/01/rdf-schema#label |
Biotest AG (2022)
|
| gptkbp:industry |
gptkb:biotechnology
pharmaceuticals |
| gptkbp:market |
gptkb:Europe
gptkb:Middle_East gptkb:South_America |
| gptkbp:numberOfEmployees |
~2,000
|
| gptkbp:parentCompany |
Grifols S.A.
|
| gptkbp:products |
plasma proteins
biotherapeutic drugs |
| gptkbp:publiclyTraded |
yes
|
| gptkbp:stockExchange |
gptkb:Frankfurt_Stock_Exchange
|
| gptkbp:website |
https://www.biotest.com
|
| gptkbp:bfsParent |
gptkb:Grifols
|
| gptkbp:bfsLayer |
8
|